Psoriasis systemic lupus erythematosus and Crohn's disease.
Conditions
Interventions
BMS-986165 and rabeprazole will be given as oral tablets with 240 milliliters
(mL) of water.
During the first 4 hours after administration of the study compound the
volunteer will not be allowed t
Sponsors
BritsolMyers Squibb Research and Development
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Healthy male and female subjects - Age of 18 to 50 years (inclusive) - BMI of 18.0 to 32.0 kg/m2 (inclusive)
Exclusion criteria
Exclusion criteria: Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. Donation of blood to a blood bank or in a clinical study (except a screening visit) within 4 weeks of study drug administration (within 2 weeks for plasma only). Blood transfusion within 4 weeks of study drug administration.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PK parameters in healthy participants administered BMS-986165 alone (reference) versus in combination with rabeprazole (test): - BMS-986165: Cmax, AUC(0-T), AUC(INF) | — |
Secondary
| Measure | Time frame |
|---|---|
| PK of BMS-986165 administered alone (reference) versus in combination with rabeprazole (test) - BMS-986165: Tmax, T-Half - Total active circulating species: Cmax, AUC(0-T), AUC(INF) | — |
Countries
Netherlands
Outcome results
None listed